Rui Wu1, Dong-Ao-Lei An1, Bing-Hua Chen1, Ruo-Yang Shi1, Wei-Bo Chen2, Tong-Tong Han3, Lian-Ming Wu1, and Jian-Rong Xu1
1Radiology, Ren Ji Hospital, School of Medicine,Shanghai Jiao Tong University, Shanghai, China, 2Philips Healthcare,shanghai, China, Shanghai, China, 3Clinical Application, Circle Cardiovascular Imaging, Calgary, Canada
Synopsis
The prognostic value of the
apparent diffusion coefficient (ADC) for diffuse myocardial fibrosis and its
relationship to the contractile function is still not investigated.
A
total of 45 HCM patients and 20 controls underwent a 3.0-T cardiac magnetic
resonance imaging (CMRI), including cine, T1 mapping, and DWI.
ADC values
in the ECV ≥ 29.6% group were significantly increased compared to the ECV < 29.6% group. ADC values were linearly
associated with 3D LV GCS, GLS, GCSR, GLSR and GRSR.
Impairment of contractile function in HCM is predominantly associated
with the contrast-free ADC value.
Abstract
INTRODUCTION: Hypertrophic
cardiomyopathy (HCM) is a hereditary disorder resulting in cardiac
sarcomere protein gene mutations, which usually presents as otherwise
unexplained left ventricular hypertrophy(1-4).Currently,
myocardial extracellular volume (ECV) has been repeatedly histologically
validated for quantification of diffuse myocardial fibrosis, and can be
acquired noninvasively with T1 mapping before and after gadolinium
administration(5-9).Diffusion
weighted imaging (DWI) has been histologically validated in detecting regions
of myocardial fibrosis in MI scar tissue(10)
and diffuse myocardial fibrosis in the failing heart(11). Despite this sensitivity, its prognostic value for
diffuse myocardial fibrosis and its relationship to the contractile function is
still not investigated. We explore the prognostic value of the apparent
diffusion coefficient (ADC) for detecting diffuse myocardial fibrosis and its
relationship to dysfunction of global contractile function in hypertrophic cardiomyopathy (HCM).
METHODS: A total of 45 HCM patients (25 male; 52 ±10 years) and
20 controls without previous cardiovascular diseases (9 male; 50 ± 6 years)
underwent a 3.0-T cardiac magnetic resonance imaging (CMRI). The CMRI sequences
included cine, T1 mapping, and DWI. The mean T1 value, ADC, extracellular
volume (ECV) and three-dimensional (3D) tissue tracking for global strain (S)
and strain rate (SR) were determined for each subject.
RESULTS: The value of ECV was 23.6 ± 3.0% for control. ECV ≥
29.6% and ECV
< 29.6% groups were classified based on the ECV values (+2SD) of control subjects. ADC values in the ECV ≥
29.6% group were significantly increased compared to the ECV < 29.6%
group, (2.63 ± 0.23 μm2/ms vs. 2.18 ± 0.28 μm2/ms).
ADC values were linearly associated with ECV values (R2 = 0.62) in
HCM patients. Using the ECV values as the gold
standard for the receiver operating
characteristic (ROC), the
area under the curve (AUC) was 0.93, 95% Confidence interval (CI) was 0.855 to
1.000 and the cut off value was 2.01 μm2/ms, sensitivity was 91.11% and specificity
was 100%. The 3D LV GCS, GLS, GRS, GCSR, GLSR and GRSR in the
ECV ≥ 29.6% group were significantly impaired compared to the
ECV
< 29.6% group. ADC values were linearly
associated with 3D LV GCS, GLS, GCSR, GLSR and GRSR (R2 =
0.33, R2 = 0.30, R2 = 0.18, R2 = 0.14, R2
= 0.24, respectively).
DISCUSSION: In
this study, we demonstrated that ADC values were capable of not only detecting
diffuse fibrosis, but also of characterizing the development of myocardial
fibrosis in HCM patients. Moreover, we found that increased ADC values were
linearly associated with the impaired deformation function in HCM patients.
ADC values play a role in interpreting the underlying changes within the
intracellular spaces of the myocardium. Recently, the potential of DWI to
identify myocardial fibrosis in clinical configurations has been investigated.
Pop et al and Nguyen et al demonstrated histological validation of the ADC
value for detecting the replacement fibrosis in infarcted swine heart and
showed that the ADC values were capable of detecting fibrosis defined by LGE
with high sensitivity and specificity, respectively(10,12).
Interestingly, the ADC values in the ECV < 29.6% group were higher than the cut off value derived from the
ROC curve.
The potential mechanisms that lead from sarcomere dysfunction to overt
hypertrophy may be multi-factored and include impaired calcium cycling,
interstitial fibrosis, myocardial oedema and microvascular dysfunction(13).
All 3D LV global strain and strain rate values were significantly
reduced in the ECV≥29.6% group, compared to the ECV<29.6% group, which
suggests that diffuse myocardial fibrosis may result in the dysfunction of
myocardial deformation. Previously, Swoboda et al(14)
demonstrated that LV segment strain in an ECV abnormal group of HCM patients
was significantly impaired. Additionally, Bogarapu et al(15) reported the utility of the 3D
LV strain and strain rate derived from CMRI feature tracking in identifying
myocardial fibrosis defined by LGE.
In this study, 3D LV GCS, GLS, GCSR, GLSR and GRSR values were
associated with increasing ADC values. Previously, we showed that increased
values of the ADC were linearly associated with impaired end systolic
circumferential global strain and end diastolic circumferential global strain
rate in HTN patients(16).
A possible mechanism linking the ADC value to decreased systolic strain in such
patients is as follows: increased extracellular matrix deposition leads to
increased LV stiffness, which decreased the end-diastolic muscle fibre length,
and through the Frank-Starling mechanism, leads to decreased cardiac muscle
contraction and LV systolic strain.
CONCLUSION: Impairment of contractile function in HCM is
predominantly associated with the contrast-free ADC value, which is a feasible
alternative to ECV for the identification of myocardial fibrosis in patients
with HCM.Acknowledgements
Supported by National
Natural Science Foundation of China (Youth Program No.81401403), Shanghai
Municipal Commission of Health and Family Planning excellent young talent
program(No. 2017YQ031) and Shanghai Jiao Tong University
Medical engineering cross fund (YG2014MS48).References
1. Gersh BJ, Maron BJ, Bonow RO, et al. 2011
ACCF/AHA guideline for the diagnosis and treatment of hypertrophic
cardiomyopathy: a report of the American College of Cardiology Foundation/American
Heart Association Task Force on Practice Guidelines. Circulation
2011;124(24):e783-831.
2. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC
Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task
Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the
European Society of Cardiology (ESC). European heart journal
2014;35(39):2733-2779.
3. Maron MS, Maron BJ, Harrigan C, et al. Hypertrophic
cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic
resonance. Journal of the American College of Cardiology 2009;54(3):220-228.
4. Urbano-Moral JA, Rowin EJ, Maron MS, Crean A, Pandian NG.
Investigation of global and regional myocardial mechanics with 3-dimensional
speckle tracking echocardiography and relations to hypertrophy and fibrosis in
hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2014;7(1):11-19.
5. Zeng M, Qiao Y, Wen Z, et al.
The Association between Diffuse Myocardial Fibrosis on Cardiac Magnetic
Resonance T1 Mapping and Myocardial Dysfunction in Diabetic Rabbits. Scientific
reports 2017;7:44937.
6. de Meester de Ravenstein C, Bouzin C, Lazam S, et al.
Histological Validation of measurement of diffuse interstitial myocardial
fibrosis by myocardial extravascular volume fraction from Modified Look-Locker
imaging (MOLLI) T1 mapping at 3 T. Journal of cardiovascular magnetic resonance
: official journal of the Society for Cardiovascular Magnetic Resonance
2015;17:48.
7. Miller CA, Naish JH, Bishop P, et al. Comprehensive
validation of cardiovascular magnetic resonance techniques for the assessment
of myocardial extracellular volume. Circulation Cardiovascular imaging
2013;6(3):373-383.
8. Flett AS, Hayward MP, Ashworth MT, et al. Equilibrium
contrast cardiovascular magnetic resonance for the measurement of diffuse
myocardial fibrosis: preliminary validation in humans. Circulation
2010;122(2):138-144.
9. White SK, Sado DM, Fontana M, et al. T1
mapping for myocardial extracellular volume measurement by CMR: bolus only
versus primed infusion technique. JACC Cardiovascular imaging
2013;6(9):955-962.
10. Nguyen C, Fan
Z, Xie Y, et al. In vivo contrast free chronic myocardial infarction
characterization using diffusion-weighted cardiovascular magnetic resonance.
Journal of cardiovascular magnetic resonance : official journal of the Society
for Cardiovascular Magnetic Resonance 2014;16:68.
11. Abdullah OM, Drakos
SG, Diakos NA, et al. Characterization of diffuse fibrosis in the failing human
heart via diffusion tensor imaging and quantitative histological validation.
NMR in biomedicine 2014;27(11):1378-1386.
12. Pop M, Ghugre NR, Ramanan V, et al. Quantification of
fibrosis in infarcted swine hearts by ex vivo late gadolinium-enhancement and
diffusion-weighted MRI methods. Physics in medicine and biology 2013;58(15):5009-5028.
13. Watkins H, Ashrafian H, McKenna WJ. The genetics of
hypertrophic cardiomyopathy: Teare redux. Heart (British Cardiac Society)
2008;94(10):1264-1268.
14. Bogarapu S, Puchalski MD,
Everitt MD, Williams RV, Weng HY, Menon SC. Novel Cardiac Magnetic Resonance
Feature Tracking (CMR-FT) Analysis for Detection of Myocardial Fibrosis in
Pediatric Hypertrophic Cardiomyopathy. Pediatric cardiology 2016;37(4):663-673.
15. Swoboda PP, McDiarmid AK, Erhayiem B, et al. Effect of
cellular and extracellular pathology assessed by T1 mapping on regional
contractile function in hypertrophic cardiomyopathy. Journal of cardiovascular
magnetic resonance : official journal of the Society for Cardiovascular
Magnetic Resonance 2017;19(1):16.
16. Wu LM, Wu R, Ou YR, et al.
Fibrosis quantification in Hypertensive Heart Disease with LVH and Non-LVH:
Findings from T1 mapping and Contrast-free Cardiac Diffusion-weighted imaging.
Scientific reports 2017;7(1):559.